Other analysts also recently issued research reports about the company. B. Riley boosted their price objective on Celsius from $130.00 to $140.00 in a research note on Thursday. Stifel Nicolaus boosted their price objective on Celsius from $93.00 to $115.00 and gave the stock a buy rating in a research note on Tuesday, August 2nd. UBS Group boosted their price objective on Celsius from $74.00 to $123.00 and gave the stock a buy rating in a research note on Thursday, August 11th. Finally, Wedbush assumed coverage on Celsius in a research note on Monday, October 10th. They issued a neutral rating and a $90.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Celsius currently has a consensus rating of Moderate Buy and a consensus target price of $101.14.
Celsius Stock Performance
Shares of CELH stock opened at $93.35 on Thursday. Celsius has a 1 year low of $38.31 and a 1 year high of $118.19. The stock has a fifty day moving average of $91.80 and a two-hundred day moving average of $81.13. The firm has a market capitalization of $7.06 billion, a PE ratio of -44.45 and a beta of 1.83.
Insider Transactions at Celsius
In other news, Director Hal Kravitz sold 5,000 shares of the stock in a transaction that occurred on Tuesday, August 23rd. The stock was sold at an average price of $110.00, for a total value of $550,000.00. Following the completion of the transaction, the director now directly owns 21,797 shares of the company’s stock, valued at approximately $2,397,670. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CEO John Fieldly sold 70,000 shares of the stock in a transaction that occurred on Wednesday, August 24th. The stock was sold at an average price of $115.55, for a total transaction of $8,088,500.00. Following the sale, the chief executive officer now directly owns 311,619 shares in the company, valued at approximately $36,007,575.45. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Hal Kravitz sold 5,000 shares of the stock in a transaction that occurred on Tuesday, August 23rd. The stock was sold at an average price of $110.00, for a total value of $550,000.00. Following the sale, the director now owns 21,797 shares in the company, valued at $2,397,670. The disclosure for this sale can be found here. 2.70% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Celsius
A number of large investors have recently bought and sold shares of CELH. Parkside Financial Bank & Trust grew its position in Celsius by 224.0% during the 3rd quarter. Parkside Financial Bank & Trust now owns 311 shares of the company’s stock worth $28,000 after acquiring an additional 215 shares during the last quarter. Quadrant Capital Group LLC grew its position in Celsius by 437.6% during the 3rd quarter. Quadrant Capital Group LLC now owns 457 shares of the company’s stock worth $41,000 after acquiring an additional 372 shares during the last quarter. Wipfli Financial Advisors LLC bought a new stake in Celsius during the 3rd quarter worth approximately $42,000. C M Bidwell & Associates Ltd. bought a new position in Celsius in the 2nd quarter valued at $44,000. Finally, Selective Wealth Management Inc. bought a new position in Celsius in the 2nd quarter valued at $52,000. 55.30% of the stock is currently owned by institutional investors.
Celsius Company Profile
Celsius Holdings, Inc develops, processes, markets, distributes, and sells functional drinks and liquid supplements in North America, Europe, Asia, and internationally. It offers various carbonated and non-carbonated functional energy drinks under the CELSIUS Originals name; dietary supplement in carbonated flavors, including apple jack'd, orangesicle, inferno punch, cherry lime, blueberry pomegranate, strawberry dragon fruit, tangerine grapefruit, and jackfruit under the CELSIUS HEAT name; and branched-chain amino acids functional energy drink that fuels muscle recovery under the CELSIUS BCCA+ENERGY name.
- Get a free copy of the StockNews.com research report on Celsius (CELH)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
Receive News & Ratings for Celsius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsius and related companies with MarketBeat.com's FREE daily email newsletter.